% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{FoltynDumitru:300832,
author = {M. Foltyn-Dumitru and R. Banan and M. Schell and M. A.
Mahmutoglu and T. Kessler$^*$ and W. Wick$^*$ and G.
Brugnara$^*$ and M. Bendszus and F. Sahm$^*$ and P.
Vollmuth$^*$},
title = {{H}istopathological and molecular characteristics of
{IDH}-wildtype glioblastoma without contrast enhancement:
implications for clinical outcomes.},
journal = {Neuro-Oncology},
volume = {27},
number = {7},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2025-00943},
pages = {1878-1887},
year = {2025},
note = {#LA:E230# / 2025 Sep 8;27(7):1878-1887},
abstract = {Glioblastoma (GB) heterogeneity poses substantial
challenges for diagnosis and treatment. IDH-wildtype GB may
lack contrast enhancement on MRI and exhibit a 'low-grade
radiologic appearance' (non-CE GB), a phenomenon with
unclear clinical implications. This study investigates the
histopathological and molecular differences and survival
outcomes between contrast-enhancing (CE) and non-CE GB.This
retrospective study at Heidelberg University Hospital
analyzed 457 IDH-wildtype GB cases (09/2009-01/2021).
Contrast enhancement on preoperative MRI was volumetrically
assessed, classifying tumors as non-CE/CE GB using a 1 cm³
cut-off. Molecular and histopathological features, including
microvascular proliferation, necrosis, and overall survival
(OS), were compared between the groups.Of the initial
cohort, 352 $(77\%)$ patients met the inclusion criteria,
with 44 $(12.5\%)$ non-CE and 308 $(87.5\%)$ CE GB. The
histopathological assessment revealed that non-CE GB was
less likely to present traditional hallmarks of
glioblastoma, such as microvascular proliferation $(39\%$
vs. $94\%)$ and necrosis $(25\%$ vs. $92\%)$ (p<0.001). In
the non-CE group, 24 patients $(55\%)$ were diagnosed as
molecular-GB, compared to only 8 patients $(3\%)$ in the CE
group (p < 0.001). A significant difference was observed in
Ki-67 levels, with non-CE GBs having a lower mean Ki-67
index of 18 ± $12\%$ compared to 26 ± $13\%$ in CE tumors
(p<0.001). The median OS was 27.2 months $(95\%CI$ 19.8-NA)
for non-CE and 14.7 months $(95\%$ CI, 13.2-17.1) for CE GB
(p=0.0049).IDH-wildtype GBs without contrast enhancement are
often diagnosed based on molecular criteria due to less
frequent histopathological hallmarks and are associated with
prolonged OS.},
keywords = {IDH-wildtype glioblastoma (Other) / MRI (Other) /
contrast-enhancement (Other) / histopathology (Other) /
low-grade radiologic appearance (Other)},
cin = {B320 / E230 / B300 / HD01},
ddc = {610},
cid = {I:(DE-He78)B320-20160331 / I:(DE-He78)E230-20160331 /
I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40108725},
doi = {10.1093/neuonc/noaf070},
url = {https://inrepo02.dkfz.de/record/300832},
}